Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer

Oncology

Volumn 71, Issue 3-4, 2007, Pages 168-175

  Henry, N Lynn ^a   Dunn, Rodney ^b   Merjaver, Sofia ^a,b   Pan, Quintin ^a   Pienta, Kenneth J ^a,b   Brewer, George ^a   Smith, David C ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NONE   (United States)

Author keywords

Antiangiogenesis; Prostate cancer, hormone refractory; Tetrathiomolybdate

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CERULOPLASMIN; COPPER; INTERLEUKIN 6; INTERLEUKIN 8; PROSTATE SPECIFIC ANTIGEN; TETRATHIOMOLYBDIC ACID; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CERULOPLASMIN BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; COPPER BLOOD LEVEL; COPPER DEFICIENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEMATURIA; HUMAN; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NEUTROPENIA; PATIENT ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SYMPTOMATOLOGY; TREATMENT FAILURE; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ADENOCARCINOMA; AGED; ANGIOGENESIS INHIBITORS; BIOLOGICAL MARKERS; CERULOPLASMIN; CHELATING AGENTS; COPPER; DISEASE PROGRESSION; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; MOLYBDENUM; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 34548083741     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106066     Document Type: Article

References (15)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
3. Choy M, Rafii S: Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest 2001;19:181-191.
4. Shariat SF, Anwuri VA, Lamb DJ, et al: Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22:1655-1663.
5. Brem SS, Zagzag D, Tsanaclis AM, et al: Inhibition of angiogenesis and tumor growth in the brain: suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am J Pathol 1990;137:1121-1142.
6. Parke A, Bhattacherjee P, Palmer RM, et al: Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 1988;130:173-178.
7. Yoshida D, Ikeda Y, Nakazawa S: Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995;37:287-292.
8. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al: Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48:42-47.
9. Cox C, Teknos TN, Barrios M, et al: The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111:696-701.
10. Pan Q, Kleer CG, van Golen KL, et al: Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-4859.
11. Brewer GJ, Dick RD, Grover DK, et al: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 2000;6:1-10.
12. Redman BG, Esper P, Pan Q, et al: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9:1666-1672.
13. Drake MJ, Robson W, Mehta P, et al: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822-827.
14. Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
15. Dahut WL, Gulley JL, Arlen PM, et al: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-2539.